stockrow
Monday 9 November 2026
Export LXEO’s income statement to Excel — free account
Lexeo Therapeutics, Inc.
LXEOLexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00.
- EPS
- +50.0%
- Free cash flow
- +35.6%
- Total debt
- −83.5%
Quarter to June 2026, against a year earlier
2.89
0.02
−0.69%
Follow LXEO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 1 | 2 | 1 | — | — | — | — | +12.3% | — | — | 47 | — | |
| Gross margin, % | — | — | — | — | 0.00 | 99.19 | 100.00 | — | — | — | 0.00 | +100.0 pt | ||||||
| EBT | — | — | — | — | (5) | (51) | (59) | (66) | (98) | (100) | (87) | +80.9% | ||||||
| EBT margin, % | — | — | — | — | (993.79) | (3,054.84) | (9,063.76) | 0.00 | 0.00 | 0.00 | 0.00 | +993.8 pt | ||||||
| Net income | — | — | — | — | (5) | (51) | (59) | (66) | (98) | (100) | (87) | +80.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.02 | 0.06 | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (0.19) | (1.90) | (36.36) | (12.40) | (3.09) | (1.86) | (1.15) | +57.8% | ||||||
| Cash flow | — | — | — | — | (0.12) | (1.66) | (33.47) | (11.11) | (2.55) | (1.84) | (1.03) | +73.3% | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | (0.55) | (0.03) | (0.02) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.12) | (1.66) | (34.03) | (11.14) | (2.57) | (1.84) | (1.04) | +73.4% | ||||||
| Book value | — | — | — | — | 0.96 | 4.86 | (69.30) | 21.21 | 3.68 | 4.60 | 2.75 | +36.7% | ||||||
| Shares, m | — | — | — | — | 27 | 27 | 2 | 5 | 32 | 54 | 70 | +15.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 1.05 | 0.0 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | 0.22 | 0.22 | 0.22 | — | — | — | (0.45) | 0.2 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (3) | (44) | (55) | (59) | (81) | (99) | (88) | +99.3% | |||||
| Capex | — | — | — | — | — | 0 | (1) | 0 | 0 | 0 | 0 | +20.6% | ||||||
| Free cash flow | — | — | — | — | (3) | (44) | (55) | (60) | (82) | (99) | (89) | +99.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 29 | 129 | 66 | 107 | 103 | 172 | 202 | +43.0% | |||||
| Net debt | — | — | — | — | (26) | (136) | (76) | (120) | (121) | (181) | (212) | +47.1% | ||||||
| Shareholders’ equity | — | — | — | — | 26 | 129 | (113) | 114 | 117 | 247 | 235 | +57.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | 0.00 | (60.89) | (50.68) | (56.06) | (68.58) | (48.10) | (40.50) | (48.1) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (104.69) | (253.48) | (104.7) pt | ||||||
| ROE | — | — | — | — | 0.00 | 165.60 | 70.34 | (22,855.08) | (85.37) | (55.00) | (46.76) | (55.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 53 | 58 | 72 | 59 | — | +3.6% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Sep 2022
Lexeo Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics, Inc. | $258.0M | — (loss-making) | — (loss-making) | −61.34% (below 0%: shrinking) | n/m | −32.40% (below 0%: shrinking) | 100.00% | (834.71%) | Compare |
| CUVL Clinuvel Pharmaceuticals Ltd. - Sponsored ADR | $257.5M | — | — | — | — | — | — | — | Compare |
| CAMP CAMP4 Therapeutics Corporation | $254.8M | — (loss-making) | — (loss-making) | +138.87% (above 0%: growing) | n/m | +20.36% (above 0%: growing) | 100.00% | (738.76%) | Compare |
| LRMR Larimar Therapeutics, Inc. | $248.3M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $241.3M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABEO Abeona Therapeutics Inc. | $238.5M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| IMRX Immuneering Corporation | $238.3M | — (loss-making) | — (loss-making) | −99.74% (below 0%: shrinking) | n/m | −40.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXEO Lexeo Therapeutics, Inc. | $237.2M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | |
| FATE Fate Therapeutics, Inc. | $223.1M | — (loss-making) | — (loss-making) | +9.18% (above 0%: growing) | n/m | +8.96% (above 0%: growing) | 100.00% | (1,495.39%) | Compare |
| Median of peers | $244.8M | — | — | +9.18% | — | +8.96% | 100.00% | (119.97%) |